Astrazeneca Plc (AZN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2014 | 12-2013 | 12-2012 | 12-2011 | 12-2010 | |
| Cash Flows From Operating Activities | |||||
| Accounts receivable | 311,000 | -383,000 | 755,000 | -1,108,000 | 10,000 |
| Other Working Capital | 2,508,000 | 166,000 | -706,000 | -897,000 | 82,000 |
| Other Operating Activity | 4,239,000 | 7,617,000 | 6,899,000 | 9,826,000 | 10,588,000 |
| Operating Cash Flow | $7,058,000 | $7,400,000 | $6,948,000 | $7,821,000 | $10,680,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -854,000 | -673,000 | -473,000 | -737,000 | -708,000 |
| Net Acquisitions | -4,531,000 | -1,158,000 | -1,187,000 | 1,772,000 | -348,000 |
| Purchase Of Investment | -130,000 | -91,000 | -46,000 | -2,754,000 | -273,000 |
| Sale Of Investment | 93,000 | 168,000 | 3,662,000 | 0 | 5,000 |
| Purchase Sale Intangibles | -1,740,000 | -1,281,000 | -3,947,000 | -458,000 | -1,180,000 |
| Other Investing Activity | 130,000 | 181,000 | 132,000 | 155,000 | 374,000 |
| Investing Cash Flow | $-7,032,000 | $-2,889,000 | $-1,859,000 | $-2,022,000 | $-2,340,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 520,000 | -5,000 | 687,000 | 46,000 | -8,000 |
| Debt Issued | 919,000 | 0 | 1,980,000 | N/A | 0 |
| Debt Repayment | -750,000 | 0 | -1,750,000 | 0 | -1,741,000 |
| Common Stock Issued | 279,000 | 482,000 | 429,000 | 409,000 | 494,000 |
| Common Stock Repurchased | 0 | 0 | -2,635,000 | -6,015,000 | -2,604,000 |
| Dividend Paid | -3,521,000 | -3,461,000 | -3,665,000 | -3,764,000 | -3,361,000 |
| Other Financing Activity | -152,000 | -63,000 | 31,000 | 3,000 | 0 |
| Financing Cash Flow | $-2,705,000 | $-3,047,000 | $-4,923,000 | $-9,321,000 | $-7,220,000 |
| Exchange Rate Effect | -152,000 | -65,000 | -4,000 | -25,000 | 33,000 |
| Beginning Cash Position | 8,995,000 | 7,596,000 | 7,434,000 | 10,981,000 | 9,828,000 |
| End Cash Position | 6,164,000 | 8,995,000 | 7,596,000 | 7,434,000 | 10,981,000 |
| Net Cash Flow | $-2,679,000 | $1,464,000 | $166,000 | $-3,522,000 | $1,120,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 7,058,000 | 7,400,000 | 6,948,000 | 7,821,000 | 10,680,000 |
| Capital Expenditure | -2,752,000 | -2,058,000 | -4,619,000 | -1,297,000 | -2,181,000 |
| Free Cash Flow | 4,306,000 | 5,342,000 | 2,329,000 | 6,524,000 | 8,499,000 |